Oral Mucositis Market Report 2026

The oral mucositis market size has grown strongly in recent years. It will grow from $1.55 billion in 2025 to $1.67 billion in 2026 at a compound annual growth rate (CAGR) of 7.6%. The growth in the historic period can be attributed to increasing use of high-dose chemotherapy regimens, rising prevalence of head and neck cancers, growing number of hematopoietic stem cell transplant procedures, limited availability of effective preventive therapies, increasing hospitalization rates for cancer treatment complications.

The oral mucositis market size is expected to see strong growth in the next few years. It will grow to $2.21 billion in 2030 at a compound annual growth rate (CAGR) of 7.3%. The growth in the forecast period can be attributed to growing investment in oncology supportive care research, increasing approval of novel mucositis therapeutics, rising awareness of early diagnosis and management of oral mucositis, expanding oncology treatment infrastructure in emerging markets, increasing focus on patient-centric cancer care approaches. Major trends in the forecast period include rising incidence of chemotherapy and radiotherapy induced oral mucositis, increasing adoption of targeted and biologic therapies for mucositis management, growing focus on preventive oral care protocols in oncology settings, rising demand for liquid and easy-to-administer dosage forms, increasing clinical emphasis on improving quality of life for cancer patients.

The rising prevalence of cancer is expected to drive growth in the oral mucositis market in the coming years. Cancer is characterized by uncontrolled growth and spread of abnormal cells that can invade and destroy normal tissues. The increasing number of cancer cases is driven by factors such as aging populations, lifestyle changes, environmental exposures, infections, and genetic predisposition. Oral mucositis treatment helps cancer patients by reducing pain and inflammation, preventing secondary infections, and promoting faster healing of oral tissues, thereby improving comfort, nutritional intake, and overall quality of life during chemotherapy or radiation therapy. For example, in May 2024, according to the National Cancer Institute, a US-based government agency, approximately 20 million new cancer cases and 9.7 million cancer-related deaths were recorded worldwide in 2022. These numbers are projected to rise to 29.9 million new cases and 15.3 million deaths annually by 2040. The growing prevalence of cancer is therefore driving demand for oral mucositis treatments.

Companies in the oral mucositis market are developing innovative solutions, such as cryotherapy, to reduce the severity and incidence of the condition. Cryotherapy involves using extreme cold to protect or treat tissue and minimize damage to oral tissues, commonly applied in conditions like warts, tumors, or injuries. For instance, in February 2024, Chemo Mouthpiece LLC, a US-based medical device company, announced FDA approval for its Chemo Mouthpiece, an intraoral ice pack that delivers cryotherapy to the mouths of patients undergoing chemotherapy. This device helps proactively manage and prevent oral mucositis, a common and painful chemotherapy side effect.

In March 2023, EVERSANA, a US-based provider of commercialization services for life-science products, partnered with ChemoMouthpiece LLC to support the U.S. launch and commercialization of the Chemo Mouthpiece™, an intraoral cryotherapy device designed to prevent and reduce oral mucositis in chemotherapy patients. The collaboration aims to enhance patient quality of life by reducing the incidence and severity of oral mucositis, improving adherence to cancer treatment. This partnership highlights the oral mucositis market’s growing focus on innovative supportive care solutions and medical devices. ChemoMouthpiece LLC is a U.S.-based medical device company.

Major companies operating in the oral mucositis market are Mundipharma International Limited, EUSA Pharma, Galera Therapeutics Inc., Enzychem Lifesciences Corporation, Oragenics Inc., Soligenix Inc., Monopar Therapeutics Inc., EpicentRx, Cellceutix Corporation, GlycoMira Therapeutics Inc., Solasia Pharma KK, 3M Healthcare, GlaxoSmithKline plc, Pfizer Inc., Colgate‑Palmolive Company, CANbridge Pharmaceuticals Inc., Helsinn Healthcare SA, Camurus AB, Norgine B.V., Clinigen Group plc, Alliance Pharma plc, Amag Pharmaceuticals, Izun Pharmaceuticals Corporation, Spherium Biomed, Mission Pharmacal, Access Pharmaceuticals Inc., Otsuka Pharmaceuticals.

North America was the largest region in the oral mucositis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oral mucositis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the oral mucositis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the oral mucositis market by raising costs for imported active pharmaceutical ingredients, formulation excipients, and specialized manufacturing equipment used in solid and liquid dosage forms. Hospital pharmacies, oncology hospitals, and retail pharmacies in north america, europe, and asia-pacific are most affected due to reliance on global supply chains. Higher tariffs have moderately increased treatment costs and procurement expenses. However, they have also encouraged local drug manufacturing, regional sourcing strategies, and investment in domestic oncology supportive care production capabilities.

The oral mucositis market research report is one of a series of new reports that provides oral mucositis market statistics, including oral mucositis industry global market size, regional shares, competitors with a oral mucositis market share, detailed oral mucositis market segments, market trends and opportunities, and any further data you may need to thrive in the oral mucositis industry. This oral mucositis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Oral mucositis is a condition marked by inflammation and ulceration of the mucous membranes lining the mouth. It commonly occurs as a side effect of cancer treatments, particularly chemotherapy and radiation therapy, which damage the rapidly dividing cells of the oral mucosa.

The main indications for oral mucositis include chemotherapy, radiotherapy, and hematopoietic stem cell transplantation. Chemotherapy-induced oral mucositis arises when chemotherapy drugs damage the rapidly dividing cells in the mouth, causing painful ulcers and inflammation. Treatments are available in solid and liquid dosage forms and include medications such as palifermin, amifostine, chlorhexidine, sucralfate, avasopasem, and dusquetide. These products are distributed through hospital pharmacies, retail pharmacies, and online pharmacies, and are used by hospitals, dental clinics, oncology hospitals, and research institutes.

The oral mucositis market consists of revenues earned by entities by providing services such as low-level laser therapy, nutritional support, and cryotherapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The oral mucositis market also includes sales of mouthwashes and rinses, gels, sprays, or films, topical analgesics and anesthetics, and anti-inflammatory agents. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.